loading
Precedente Chiudi:
$464.00
Aprire:
$468.68
Volume 24 ore:
771.27K
Relative Volume:
0.66
Capitalizzazione di mercato:
$60.75B
Reddito:
$2.46B
Utile/perdita netta:
$-319.09M
Rapporto P/E:
-187.86
EPS:
-2.4669
Flusso di cassa netto:
$-52.09M
1 W Prestazione:
-3.79%
1M Prestazione:
+1.10%
6M Prestazione:
+91.02%
1 anno Prestazione:
+57.80%
Intervallo 1D:
Value
$459.38
$469.29
Intervallo di 1 settimana:
Value
$456.90
$495.55
Portata 52W:
Value
$205.87
$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Nome
Alnylam Pharmaceuticals Inc
Name
Telefono
(617) 551-8200
Name
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Dipendente
2,230
Name
Cinguettio
@alnylam
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
ALNY's Discussions on Twitter

Confronta ALNY con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
463.43 60.82B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.39 108.36B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.95 61.02B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
817.32 50.01B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
310.81 34.05B 4.56B -176.77M 225.30M -1.7177

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-04 Aggiornamento Oppenheimer Perform → Outperform
2025-08-04 Aggiornamento Wolfe Research Underperform → Peer Perform
2025-07-30 Ripresa Raymond James Outperform
2025-07-21 Iniziato Truist Buy
2025-03-31 Iniziato Redburn Atlantic Buy
2025-03-24 Aggiornamento JP Morgan Neutral → Overweight
2024-11-12 Downgrade Wolfe Research Peer Perform → Underperform
2024-10-16 Iniziato Scotiabank Sector Outperform
2024-08-16 Aggiornamento Goldman Neutral → Buy
2024-02-16 Downgrade Goldman Buy → Neutral
2024-02-15 Iniziato Wolfe Research Peer Perform
2023-12-08 Iniziato Wells Fargo Equal Weight
2023-10-11 Downgrade Oppenheimer Outperform → Perform
2023-09-29 Iniziato Raymond James Outperform
2023-05-05 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-26 Iniziato SMBC Nikko Neutral
2023-03-21 Iniziato Bernstein Outperform
2023-01-18 Iniziato Canaccord Genuity Buy
2022-09-09 Ripresa Morgan Stanley Equal-Weight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-06-27 Downgrade Guggenheim Buy → Neutral
2022-06-07 Iniziato William Blair Outperform
2022-04-25 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-03-01 Iniziato Citigroup Buy
2022-02-03 Aggiornamento Guggenheim Neutral → Buy
2022-01-03 Aggiornamento Piper Sandler Neutral → Overweight
2021-11-22 Aggiornamento Goldman Neutral → Buy
2021-11-22 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Aggiornamento Oppenheimer Perform → Outperform
2021-10-04 Aggiornamento UBS Neutral → Buy
2021-08-04 Downgrade Piper Sandler Overweight → Neutral
2021-02-22 Downgrade Guggenheim Buy → Neutral
2021-02-12 Downgrade Citigroup Buy → Neutral
2021-02-12 Reiterato H.C. Wainwright Buy
2021-01-25 Downgrade BMO Capital Markets Outperform → Market Perform
2020-09-30 Ripresa Berenberg Hold
2020-09-08 Iniziato Citigroup Buy
2020-08-11 Downgrade Oppenheimer Outperform → Perform
2020-05-13 Iniziato RBC Capital Mkts Sector Perform
2020-05-07 Downgrade JP Morgan Overweight → Neutral
2020-04-24 Ripresa Evercore ISI Outperform
2020-03-19 Iniziato Berenberg Buy
2019-12-19 Reiterato Chardan Capital Markets Buy
2019-11-20 Iniziato Oppenheimer Outperform
2019-11-13 Iniziato BofA/Merrill Buy
2019-05-23 Ripresa Goldman Neutral
2019-04-12 Iniziato Evercore ISI Outperform
2019-03-06 Aggiornamento Evercore ISI In-line → Outperform
2019-03-05 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-01-23 Iniziato UBS Neutral
2018-10-01 Iniziato Cantor Fitzgerald Overweight
2018-08-13 Reiterato Stifel Buy
2018-08-07 Aggiornamento Stifel Hold → Buy
2018-05-04 Reiterato Stifel Hold
2018-03-28 Iniziato Evercore ISI In-line
Mostra tutto

Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie

pulisher
09:38 AM

Why Alnylam Pharmaceuticals Inc. stock is recommended by analysts2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - newser.com

09:38 AM
pulisher
08:12 AM

Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikes2025 Price Momentum & Consistent Growth Stock Picks - newser.com

08:12 AM
pulisher
07:53 AM

Has Alnylam Pharmaceuticals Inc. found a price floorInflation Watch & Technical Pattern Based Buy Signals - newser.com

07:53 AM
pulisher
04:56 AM

What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com

04:56 AM
pulisher
04:48 AM

Is Alnylam Pharmaceuticals Inc. stock resilient to inflation2025 Sector Review & Safe Entry Zone Tips - newser.com

04:48 AM
pulisher
04:31 AM

Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesWeekly Profit Report & Long-Term Capital Growth Ideas - newser.com

04:31 AM
pulisher
02:14 AM

Is it time to cut losses on Alnylam Pharmaceuticals Inc.Trade Exit Report & Advanced Swing Trade Entry Plans - newser.com

02:14 AM
pulisher
Oct 24, 2025

Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.2025 Risk Factors & AI Powered Market Entry Strategies - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

How to recover losses in Alnylam Pharmaceuticals Inc. stockWall Street Watch & Long-Term Capital Growth Ideas - newser.com

Oct 24, 2025
pulisher
Oct 23, 2025

Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Oct 23, 2025
pulisher
Oct 22, 2025

Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Market Outlook & Daily Stock Momentum Reports - newser.com

Oct 22, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 18:00:20 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Published on: 2025-10-21 15:17:29 - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Are Alnylam Shares Still Attractive After a 110% Surge and Fresh Pipeline News? - simplywall.st

Oct 21, 2025
pulisher
Oct 21, 2025

Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo

Oct 21, 2025
pulisher
Oct 21, 2025

Will Alnylam Pharmaceuticals Inc. (DUL) stock sustain bullish trend into 2025Trend Reversal & Risk Adjusted Buy/Sell Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryMarket Risk Report & Long-Term Growth Stock Strategies - newser.com

Oct 21, 2025

Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Greenstreet Yvonne
Chief Executive Officer
Oct 02 '25
Sale
452.05
8,924
4,034,085
65,409
Tanguler Tolga
EVP, Chief Commercial Officer
Oct 02 '25
Sale
452.05
1,405
635,126
27,438
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Oct 02 '25
Sale
452.05
2,441
1,103,451
25,231
Garg Pushkal
EVP Chief R&D
Oct 03 '25
Sale
451.48
3,022
1,364,387
20,221
Garg Pushkal
EVP Chief R&D
Oct 02 '25
Sale
452.05
2,937
1,327,675
23,243
$577.95
price up icon 0.39%
$817.32
price up icon 0.63%
biotechnology ONC
$310.81
price up icon 0.25%
$159.66
price down icon 0.29%
$105.66
price up icon 0.87%
Capitalizzazione:     |  Volume (24 ore):